Patricia L Allen

Director

Patricia L Allen (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Zenas BioPharma, Inc. (ZBIO). Across 1 priced purchase filing, the average 21-session return was +3.3% from execution and -9.3% from disclosure (delay-adjusted; derived). The largest single filing was $500K of ZBIO (19,860 sh across 4 lots, as filed), executed Feb 12.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+3.3%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

-9.3%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$500K

shares × price, as filed

Last traded

Feb 13

Filed Feb 13

Open performance→

Volume by month

Buys $500K Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

ZBIO

Zenas BioPharma, Inc. ZBIO · 1 buy · 0 sells 1 filing

Recent filings

ZBIOPURCHASE Zenas BioPharma, Inc. View filing → $500K
19,860 sh across 4 lots
Exec Feb 12
Filed Feb 13 · 5:06 PM ET